These findings not only enhance our understanding of A3AR ligand binding, activation, and signalling mechanisms but also provide a robust structural framework for the rational design of highly selective A3AR ligands that could lead to new treatment strategies for a wide range of disorders, including inflammatory diseases, cancer, and glaucoma. Here, ADORA3 is linked to glaucoma.